Summary by Moomoo AI
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, reported financial and operational results for the quarter ended September 30, 2024. The company recorded a net loss of $13.8 million for the quarter, compared to a net loss of $19.1 million for the same period in 2023. The net loss per share, basic and diluted, was $1.10 for the quarter, an improvement from $1.73 in the previous year. Research and development expenses decreased to $15.6 million from $24.6 million year-on-year, reflecting a strategic refocus and workforce reductions. General and administrative expenses increased to $6.7 million from $4.9 million, due to higher personnel-related expenses and professional fees. The company's cash, cash equivalents, and restricted cash totaled $60.0 million as of September 30, 2024. HOOKIPA Pharma continues to advance its proprietary immuno-oncology...Show More
